NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

VIGL

Vigil Neuroscience Inc

Jul 08 • 03:54PM ET

8.01

Dollar change +0.02
Percentage change 0.25	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB ALNY SRPT SAGE NBIX ACAD IONS CORT PRTA

| Held by: VTI VXF ARB IWC MNA AVSC RFLR BMED

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.06	Insider Own	32.98%	Shs Outstand	46.67M	Perf Week	0.75%
Market Cap	381.97M	Forward P/E	-	EPS next Y	-1.70	Insider Trans	0.00%	Shs Float	31.96M	Perf Month	1.65%
Enterprise Value	307.56M	PEG	-	EPS next Q	-0.42	Inst Own	51.23%	Short Float	0.99%	Perf Quarter	413.46%
Income	-86.73M	P/S	-	EPS this Y	11.29%	Inst Trans	12.93%	Short Ratio	0.23	Perf Half Y	352.54%
Sales	0.00M	P/B	5.74	EPS next Y	7.35%	ROA	-74.69%	Short Interest	0.32M	Perf YTD	371.17%
Book/sh	1.40	P/C	4.39	EPS next 5Y	8.10%	ROE	-102.70%	52W High	8.00 0.12%	Perf Year	102.78%
Cash/sh	1.83	P/FCF	-	EPS past 3/5Y	58.15% -19.68%	ROIC	-113.01%	52W Low	1.31 510.51%	Perf 3Y	210.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	0.28% 0.34%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.05%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	89.11	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.97	EPS Q/Q	2.74%	SMA20	1.03%	Beta	3.36	Target Price	8.00
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	37.96%	Rel Volume	0.34	Prev Close	7.99
Employees	69	LT Debt/Eq	0.18	Earnings	May 07 BMO	SMA200	138.68%	Avg Volume	1.37M	Price	8.01
IPO	Jan 07, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	7.58% -	Trades		Volume	457,254	Change	0.25%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Downgrade	Stifel	Buy → Hold	$8
Dec-04-24	Initiated	William Blair	Outperform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$13 → $4
Oct-18-23	Initiated	JMP Securities	Mkt Outperform	$23
Mar-31-23	Initiated	Mizuho	Buy	$15
Sep-16-22	Initiated	Wedbush	Outperform	$19
Aug-29-22	Initiated	H.C. Wainwright	Buy	$24
Feb-01-22	Initiated	Stifel	Buy	$24
Feb-01-22	Initiated	Morgan Stanley	Equal-Weight	$17
Feb-01-22	Initiated	Jefferies	Buy	$20
Feb-01-22	Initiated	Guggenheim	Buy	$23

Show Previous Ratings

Jun-25-25 09:55AM	Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? (Zacks)
Jun-09-25 09:55AM	Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet (Zacks)
Jun-04-25 07:00AM	Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP (GlobeNewswire)
Jun-02-25 09:55AM	Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? (Zacks)
08:54AM	Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover (Investopedia)
09:55AM	Loading…
May-23-25 09:55AM	Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade (Zacks)
May-22-25 07:50PM	Vigil Neuroscience to be acquired by Sanofi for $8.00 per share (TipRanks) +241.13%
12:20PM	Sanofi buys Vigil Neuroscience for $470m in Alzheimers push (Pharmaceutical Technology)
11:40AM	Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi (Investopedia)
10:14AM	Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout (Zacks)
10:06AM	Sanofi Inks A $470 Million Alzheimer's Deal, Sending This Dollar Stock Flying (Investor's Business Daily)
08:05AM	Sanofi gains experimental Alzheimers drug through Vigil buyout (BioPharma Dive)
07:21AM	Sanofi Boosts Alzheimer's Pipeline With Vigil Neuroscience Acquisition (Benzinga)
May-21-25 08:22PM	Sanofi to acquire Vigil Neuroscience in Alzheimers drug play (Investing.com) -6.85%
07:59PM	Sanofi to Buy Vigil Neuroscience for About $470 Million (The Wall Street Journal)
07:30PM	Loading…
07:30PM	Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi (GlobeNewswire)
May-07-25 07:00AM	Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates (GlobeNewswire)
Apr-02-25 07:00AM	Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD 2025 International Conference (GlobeNewswire) +5.36%
Mar-17-25 12:00PM	Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-13-25 07:00AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates (GlobeNewswire) -10.21%
Mar-11-25 07:00AM	Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Mar-01-25 04:51PM	Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 (Insider Monkey)
Jan-30-25 07:00AM	Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire) +7.31%
Jan-24-25 06:17AM	Mixed results for Keytruda; AbbVie to work with Neomorph (BioPharma Dive) -6.38%
Jan-23-25 11:33AM	Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 (Benzinga) +15.76%
07:00AM	Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease (GlobeNewswire)
Jan-08-25 04:05PM	Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones (GlobeNewswire)
Nov-12-24 07:00AM	Vigil Neuroscience to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 07:00AM	Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.30%
Nov-05-24 07:00AM	Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference (GlobeNewswire)
06:52AM	Loading…
Sep-18-24 06:52AM	FDA lifts partial clinical hold on Vigil Neurosciences Phase I VG-3927 trial (Clinical Trials Arena)
Sep-17-24 07:00AM	Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 (GlobeNewswire)
Sep-16-24 04:05PM	Vigil Neuroscience to Present at Cantor Global Healthcare Conference (GlobeNewswire)
Aug-29-24 07:00AM	Vigil Neuroscience to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 07:00AM	Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 04:05PM	Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics (GlobeNewswire)
Jul-30-24 04:05PM	Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC) (GlobeNewswire) -5.59% -5.01%
Jul-24-24 03:12PM	Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker (Benzinga) +6.52%
07:00AM	Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease (GlobeNewswire)
Jul-18-24 04:05PM	Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference (GlobeNewswire) -10.02%
07:00AM	Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP (GlobeNewswire)
Jun-29-24 08:26PM	Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 08:11AM	Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? (InvestorPlace) +18.52%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
02:00AM	Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi (GlobeNewswire)
Jun-11-24 06:30AM	3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition (InvestorPlace)
06:00AM	3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition (InvestorPlace)
Jun-05-24 12:55PM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks) +34.66%
May-30-24 07:05AM	Vigil Neuroscience to Present in Upcoming June Investor Conferences (GlobeNewswire) +7.74%
May-28-24 12:00PM	All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy (Zacks) -8.82%
May-08-24 07:40AM	Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference (GlobeNewswire) +18.50%
May-07-24 10:55PM	VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024 (InvestorPlace) +10.38%
09:08PM	Vigil Neuroscience Inc (VIGL) Q1 2024 Earnings: Challenges Persist Amid Clinical Developments (GuruFocus.com)
04:05PM	Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-17-24 04:05PM	Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire) -5.82%
Mar-26-24 01:53PM	VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023 (InvestorPlace) -7.00%
07:05AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:05AM	Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer (GlobeNewswire) +9.18%
Mar-13-24 07:05AM	Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-12-24 07:05AM	Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire) -5.99%
Mar-06-24 04:25PM	Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 (GlobeNewswire) +7.28%
Feb-29-24 04:05PM	Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 (GlobeNewswire)
Feb-07-24 04:05PM	Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 04:30PM	Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones (GlobeNewswire)
Nov-22-23 04:05PM	Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire) -9.17%
Nov-16-23 04:05PM	Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE (GlobeNewswire) -40.03%
Nov-07-23 07:05AM	Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.34%
Oct-18-23 09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
Oct-17-23 07:05AM	Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease (GlobeNewswire) +6.65%
Oct-05-23 04:01PM	Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire) +22.18%
Sep-26-23 07:05AM	Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP (GlobeNewswire)
Sep-11-23 12:00PM	Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting (GlobeNewswire)
Sep-08-23 04:05PM	Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program (GlobeNewswire)
07:05AM	Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-08-23 07:05AM	Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 04:05PM	Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer (GlobeNewswire) -8.33%
Jun-01-23 07:00AM	Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference (GlobeNewswire)
May-10-23 07:00AM	Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-09-23 07:00AM	Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors (GlobeNewswire)
May-08-23 08:30AM	Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
07:08AM	Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (GlobeNewswire)
Mar-30-23 07:00AM	Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 (GlobeNewswire)
Mar-22-23 07:00AM	Vigil Neuroscience to Present at Stifel 2023 CNS Days (GlobeNewswire) +10.82%
Mar-21-23 07:00AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-02-23 04:00PM	Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Jan-03-23 07:00AM	Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-22 04:01PM	Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team (GlobeNewswire)
Dec-14-22 04:01PM	Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP (GlobeNewswire) +6.66%
Nov-29-22 05:23AM	We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-28-22 07:00AM	Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022 (GlobeNewswire) +11.46%
Nov-10-22 07:00AM	Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -23.86%
Nov-07-22 07:00AM	Vigil Neuroscience to Present at Upcoming Investor Conferences (GlobeNewswire) +10.07%
Nov-02-22 12:43PM	Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease (Benzinga) -12.04%
07:00AM	Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP (GlobeNewswire)
Nov-01-22 07:00AM	Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP (GlobeNewswire)
Oct-12-22 07:58AM	7 Short-Squeeze Stocks to Buy for Contrarian Investors (InvestorPlace) +37.01%
Sep-14-22 09:55AM	Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know (Zacks)
Sep-01-22 07:00AM	Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-29-22 09:55AM	How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133% (Zacks)

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Budd Haeberlein Samantha L.	Director	Dec 19 '24	Buy	1.71	12,000	20,520	12,000	Dec 19 06:44 PM
Magovcevic-Liebisch Ivana	President and CEO	Dec 19 '24	Buy	1.68	5,000	8,400	222,687	Dec 19 06:42 PM
Magovcevic-Liebisch Ivana	President and CEO	Dec 18 '24	Buy	1.67	5,000	8,350	217,687	Dec 18 05:51 PM
Magovcevic-Liebisch Ivana	President and CEO	Dec 05 '24	Buy	2.34	5,000	11,700	212,687	Dec 05 05:09 PM
Verni Christopher	FORMER OFFICER	Sep 19 '24	Proposed Sale	3.62	40,000	145,000		Sep 19 05:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIGL

Vigil Neuroscience Inc

Upgrade your FINVIZ experience